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in H61-D cells an HIV-1 persistently infected lymphoid cell line. Three mutagenic agents: 5-hydroxy-2′-
deoxycytidine (5-OHdC), 5-ﬂuorouracil (5-FU) and 2,2′-diﬂuoro-2′-deoxycytidine (gemcitabine) were used.
After 54 passages, treatments with 5-FU and gemcitabine reduced virus infectivity, p24 and RT activity. Treat-
ment with the pyrimidine analog 5-OHdC resulted in increases of p24 production, RT activity and infectivity.
Rise in viral replication by 5-OHdC duringHIV-1 persistence is in contrast with its inhibitory effect in acute infec-
tions. Viral replication enhancement by 5-OHdC was associated with an increase in intracellular HIV-1 RNA
mutations. Mechanisms of HIV-1 replication enhancement by 5-OHdC are unknown but some potential factors
are discussed. Increase of HIV-1 replication by 5-OHdC cautions against the use, without previous analyses, of
mutagenic nucleoside analogs for AIDS treatment.
© 2012 Elsevier Inc. All rights reserved.Introduction
Lethal mutagenesis is a new antiviral approach consisting in virus
extinction by enhanced mutagenesis. The concept behind this antiviral
therapy is that the mutagenic drugs increase the already highmutation
rate of RNA viruses beyond an error threshold incompatible with the
maintenance of genetic information (Eigen, 2002). RNA viruses have
been extinguished using different protocols with the administration of
mutagenic nucleoside or base analogs such as ribavirin, 5-ﬂuorouracil
(5-FU), 5-azacytidine (5-AZC) alone or in combination with antiviral
inhibitors (Agudo et al., 2010; Contreras et al., 2002; Crotty et al.,
2001; Dapp et al., 2009; Day et al., 2005; Grande-Perez et al., 2002;
Grande-Perez et al., 2005a; Grande-Perez et al., 2005b; Holland et al.,
1990; Perales et al., 2009; Ruiz-Jarabo et al., 2003; Severson et al.,
2003; Sierra et al., 2000; Sierra et al., 2007); reviewed in (Anderson et
al., 2004; Domingo et al., 2005; Graci and Cameron, 2008). Regarding
studies with human immunodeﬁciency virus type 1 (HIV-1), in a
clinical trial, nucleoside analog KP-1461, an oral prodrug of 5-aza-ología, Instituto de Salud Carlos
d, Spain. Fax:+3491509 7919.
.
rights reserved.5,6 dihidro-2′-deoxycytidine or KP-1212 (Harris et al., 2005) has
been tested with HIV-1 infected patients and while it enhanced tran-
siently the mutation spectrum of HIV-1, it did not lead to reductions
in viral load (Mullins et al., 2011). The mutagenic pyrimidine analog
5-hydroxy-2′-deoxycytidine (5-OHdC) was successfully applied to
extinguish HIV-1 in acute cell culture infections (Loeb et al., 1999;
Tapia et al., 2005).
HIV-1 natural infections are characterized by a massive replication
during the acute primo-infection followed by a phase with continuous
viral replication which explains the consideration of HIV infections as
persistent infections. The study of HIV-1 persistence was approached
in our laboratory by the establishment of two persistently infected lym-
phoid cell lines, designatedH61 andM61 (Sanchez-Merino et al., 2007).
These cell lines showed continuous viral production but at low levels. In
contrast to the extensively studied cell lines with latent infections (like
ACH-2 and U1 cells), viral production in H61 and M61 did not increase
as a result of treatment with mitogens (Sanchez-Merino et al., 2007). A
clonal cell population, termed H61-D, was obtained by limiting dilution
fromH61 cells. This clonal cell line had continuous viral production and
evidence of new rounds of viral replication as shown by the decrease in
viral production with AZT treatment, new provirus formation, presence
of 2-LTR forms and proviral diversity (Olivares et al., unpublished
results).
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genic pyrimidine analogs on the HIV-1 resident in the persistently
infected H61-D cells. The three mutagenic drugs used were: 5-OHdC,
5-FU and gemcitabine. 5-OHdC is incorporated into DNA by DNA poly-
merases and HIV-1 reverse transcriptase (RT), yields predominantly
G>A, A>G and C>T transitions and it was successfully applied to ex-
tinguish HIV-1 in acute infections in cell culture (Loeb et al., 1999;
Tapia et al., 2005). 5-FU interfereswith the synthesis of DNA by blocking
the conversion of deoxyuridylic acid to thymidylic acid, and is a potent
mutagenic agent for RNA synthesis in several RNA viruses yielding
mainly A>G and U>C transitions (Agudo et al., 2008; Grande-Perez
et al., 2005a; Ruiz-Jarabo et al., 2003; Sierra et al., 2000). Gemcitabine
inhibits ribonucleotide reductase, and it is used to treat patients with
locally advanced or metastatic cancer of the pancreas (Burris et al.,
1997). Recently, gemcitabine has been used as a lower toxicity substi-
tute for hydroxyurea in antiretroviral therapy (Clouser et al., 2011).
In the present study, we have analyzed the effect of 5-OHdC, 5-FU
and gemcitabine, alone or in combinations, on the HIV-1 resident in
the persistently infected H61-D cells. Upon treatment with 5-FU and
gemcitabine, a reduction in viral yield was obtained. Unexpectedly,
the use of 5-OHdC resulted in an augmentation of HIV-1 replication.
This result is in contrast with previous investigations which docu-
mented strong decreases and extinction of HIV-1 infectivity mediated
by 5-OHdC in acute infections in cell culture (Loeb et al., 1999; Tapia
et al., 2005). Several possible mechanisms of a mutagen-mediated
enhancement of HIV-1 replication are considered and implications
for a lethal mutagenesis approach for HIV-1 infections are discussed.
Results
Toxicity evaluation of mutagenic drugs in an HIV-1 persistently infected
cell line
The persistently infected H61-D cell line was used for the explora-
tion of lethal mutagenesis in HIV-1. Since H61-D cells displayed a con-
tinuous but limited viral production, we assumed that it would beFig. 1. Toxicity analysis of the mutagenic drugs. Graphics show viability of H61-D cells durin
panels A, B, C the drug was added at each cell passage, whereas in panel D, (gemcitabine) w
with trypan blue following procedures in Materials and methods.necessary tomaintain the cells in permanent presence of themutagenic
agents during long periods of time to attain amutagenic effect. The pro-
longed application of the drugs in the cells could result, however, in
toxic effects. The toxicity of 5-OHdC, 5-FU or gemcitabine in H61-D
cells was quantiﬁed by counting cell viability upon mutagenic treat-
ment. Based on previous studies (Loeb et al., 1999; Sierra et al., 2000;
Tapia et al., 2005) a range of concentrations of 1–3 mM for 5-OHdC,
0.7–3 μM for 5-FU and 0.2–0.8 nM for gemcitabine was tested (Fig. 1).
From these experiments the highest drug concentrations that left cell
viability over 80% after serial passages were: 1 mM for 5-OHdC and
1.5 μM for 5-FU. The gemcitabine treatment could be applied only
once a week due to its high toxicity, and the highest concentration
tolerated was 0.6 nM (Fig. 1).Effect of mutagenic treatments on the persistently infected H61-D cells
The investigation of the mutagenic effect of 5-OHdC, 5-FU and
gemcitabine was carried out in two parallel cultures of H61-D cells
during 54 passages. Levels of p24 protein, RT activity and infectivity
(TCID50) of HIV-1 in the cell culture supernatant at passage 54 were
compared with the corresponding values for the initial cell popula-
tion (passage p0) for the different treatments. Passage of cells in the
absence of drugs resulted in an increase of viral production and
viral infectivity, presumably as a result of ﬁtness optimization of the
virus in the course of persistence (Fig. 2). At passage 54, reductions
of viral production of 16% to 49% relative to the cells cultured in the
absence of drugs were observed in all cases, except in the cells pas-
saged only in the presence of 5-OHdC. Passages in the presence of
5-OHdC resulted, surprisingly, in increases of about 18% in p24 and
RT activity, and more than 100% in infectivity. To conﬁrm this unex-
pected effect of 5-OHdC, cells were subjected to 74 additional
passages in the presence of 5-OHdC. At passage 128, the analysis con-
ﬁrmed the stimulation of HIV-1 expression by 5-OHdC (Fig. 2). Thus,
in contrast to 5-FU, gemcitabine and their combinations, 5-OHdC
stimulated HIV-1 expression from persistently infected cells.g ﬁve to nine passages in the presence of the indicated mutagens and concentrations. In
as added only once a week. Toxicity was evaluated by the quantiﬁcation of cell viability
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Fig. 2. Effect of different mutagenic treatments on HIV-1 expression in H61-D cells. Values of p24 protein (p24), RT activity (RT) and TCID50 determined in the cell cultures upon
treatment of the cells with the mutagenic treatments at passages 0, 54 and 128. The ﬁrst panel represents the values of the control cultures at passage 0 (dashed bar) versus passage
54 (empty bar). Values depicted as ﬁlled bars for the drug-treated cells are relative to the corresponding levels at passage zero without treatment (dashed bars). Passages were
performed in two parallel cultures and the values are the mean of the two replicas and of two to four determinations, standard errors are given. The differences between treated
and untreated cells were statistically signiﬁcant at (pb0.05) in all cases, using an unpaired T-test. All procedures are described in Materials and methods.
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treatment
The investigation of the enhancement of HIV-1 production in the
presence of 5-OHdC focused in several potential factors of viral activa-
tion. First, cytidine nucleoside analogs with modiﬁcations in the 5-
position of the pyrimidine ring have been described as DNA methyla-
tion inhibitors (Beumer et al., 2006; Leone et al., 2003). In addition,
the 5′-LTR provirus has been found hypermethylated in HIV-1 latentFig. 3. Methylation pattern in the 5´LTR U3 in H61-D cells. Schematic map of the CpG sites in t
pattern in the 5′LTR provirus from the control and the different treatment cultures: control cultu
Closed circles indicatemethylated and the open circles un-methylated CpG sites. The column in
quasispecies in 9 to 11 clones with its percentage in parenthesis. Procedures are described in Mcell lines (ACH-2, U1 cells) and, after cell activation with mitogens,
the increased viral expression was associated with the extensive
de-methylation in this region of proviral DNA (Ishida et al., 2006).
Among the most relevant CpG island in this 5´-LTR are nine CpG sites
in the U3 (Ishida et al., 2006). These CpG sites were analyzed in the
proviral DNA from the persistently infected cells after 54 passages in
the absence or presence of 5-OHdC, 5-FU or gemcitabine. The clonal
analysis (Fig. 3) indicated the presence of a single methylated CpG site
in the cells in the absence but also in the presence of 5-OHdC. This sitehe 5′U3 from the provirus in H61-D cells. The different graphs represent the methylation
re, 5-OHdC, 5-FU, and gemcitabine. Each line depicts themethylation pattern of one clone.
the right quantiﬁes the presence of variantswith differentmethylation pattern in the viral
aterials and methods.
150 C. Sánchez-Jiménez et al. / Virology 424 (2012) 147–153was foundmethylated in all DNA clones from cells passaged in the pres-
ence of 5-FUor gemcitabine. Unlessmethylation heterogeneity played a
role, the enhancement of viral replication in the H61-D 5-OHdC treated
cells is unlikely to be the consequence of the alteration of the methyla-
tion status at this site in the proviral DNA.
Second, NFκB is one of the main factors responsible for T cell activa-
tion and therefore it is an important mediator of HIV-1 activation and
replication (Coiras et al., 2009). In order to assess the possible role of
NFκB in the increase of HIV-1 replication mediated by 5-OHdC, the
NFκB activitywas assayed as described in (Coiras et al., 2008). However,
the difference (1.16±0.41-fold) in the NFκB activity in the H61-D cells
passaged in the absence or presence of 5-OHdC was not signiﬁcant
(data not shown).
Finally, another factor that could contribute to differences in HIV
replication associated with 5-OHdC treatment is the intracellular
level of standard ribonucleotides. Mutagenic nucleoside analogs are
converted into the corresponding active nucleotides inside the cell
(Streeter et al., 1973; Zimmerman et al., 1978). Nucleotide analogs
could affect the ribonucleotide synthetic pathways and consequently
imbalance their intracellular levels and alter provirus expression. To
quantify the ribonucleotide pools, HPLC analysis of H61-D intracellular
extracts was performed (Fig. 4). No statistically signiﬁcant effect of
treatments was observed for the concentrations of UTP (p=0.063),
CTP (p=0.465) or ATP (p=0.051), whereas it was signiﬁcant for GTP
(p=0.048). However, a Dunn's post-hoc test did not conﬁrm this
difference and only detected a signiﬁcant difference between 5-FU
plus gemcitabine combination treatment and the control on the GTP
pool (p=0.016). In summary, no signiﬁcant effects in methylation,
NFκB activity or ribonucleotides concentrations were observed after
treatment of H61-D cells with 5-OHdC that could affect expression of
HIV-1.
Nucleotide sequence analysis of intracellular viral RNAs from the treated
and untreated cultures
The potential mutagenic effect of the drugs on the HIV-1 produced
by H61-D cells was investigated by subjecting the intracellular viral
RNA from the treated and untreated cells to RT-PCR ampliﬁcation,
molecular cloning and sequencing of 718 nucleotides from the LTR-
gag region (Table 1). In the HIV-1 RNAs from passage 54 of the cellsFig. 4. Quantiﬁcation of nucleoside-triphosphate pools in drug-treated and control
H61-D cells. HPLC analysis of NTP levels was performed in cell extracts of H61-D cells
at passage 54 of control (no treatment), 1 mM 5-OHdC, 1.53 μM 5-FU, and 0.6 nM gem-
citabine or combinations of two analogs, as indicated. The nicotineamide adenine dinu-
cleotide (NAD) peak was determined by spectral analysis and used to normalize
nucleotide NTP values in fmol. The effect of each treatment on the levels of each nucle-
oside triphosphate was tested by a non-parametric Kruskal–Wallis one-way analysis of
variance. Procedures are described in Materials and methods.with either 5-OHdC alone or in combination with 5-FU or gemcitabine,
the mutation frequency approached 10×10-4 mutations/nucleotide.
The Kruskal–Wallis test followed by a Dunn's multiple comparison
tests showed a very signiﬁcant increase of the genetic heterogeneity
in the viral populations treated with 5-OHdC alone or combined with
the other mutagens at a pb0.001, while no difference was observed
with 5-FU or gemcitabine used alone (Fig. 5). The viral quasispecies
derived from the cells treated with 5-FU and gemcitabine showed also
a signiﬁcant augmentation in their heterogeneity (Table 1 and Fig. 5),
indicating a reinforcement of mutagenesis when combining these two
mutagens. Regarding the type of mutations observed in the RNAs
from the different treatments, there is a slight over-representation of
T>C changes in the 5-OHdC treated cultures. Thus 5-OHdC exerts a
limited but statistical signiﬁcant mutagenic effect on the viruses that
replicates in the persistently infected H61-D cells.
Discussion
In this study we described, in a cell line persistently infected with
HIV-1, the result of a lethal mutagenesis treatment on viral production
and virus population heterogeneity using three recognized mutagens,
5-OHdC, 5-FU, and gemcitabine.
Extinction was not expected since H61-D persistently infected cell
lines harbour integrated provirus, which are responsible for the contin-
uous viral replication, and, until now, has proven refractory to eradica-
tion.Mutagenic treatment of persistently infected cells might produce a
decrease in viral yield due to the introduction of lethal mutations in the
viral transcripts or in new provirus during the corresponding rounds
of viral replication. In fact, there is evidence of reverse transcriptase
activity and new provirus incorporation in H61-D during cell
passages (I. Olivares, unpublished results).The decrease in viral pro-
duction was observed in the present study in the treatments with
5-FU and gemcitabine. In contrast, cell cultures in the presence of
5-OHdC resulted, unexpectedly, in an increase in viral production. This
is an important observation as it is contrary to what was previously
reported when used to assess its effect on acute infection (Loeb et al.,
1999; Tapia et al., 2005) and may be able to help explain - at least in
part - the lack of reduction in viral load in clinical trial testing of KP-
1461, a related prodrug (Mullins et al., 2011).
We investigated three of themost recognized potential factors asso-
ciated with activation of viral replication in T cells: DNA methylation,
NFkB activity, and nucleotide pool concentrations. De-methylation in
the HIV-1 5′LTR promoter has been associated with HIV reactivation
from latency in ACH-2 cells (Blazkova et al., 2009; Ishida et al., 2006).
Analyzing this promoter, the same methylation pattern was observed
in the treated than in the control cultures. The methylation status
(Fig. 3) renders unlikely a correlation between the increase of HIV-1
expression by 5-OHdC and DNA proviral methylation. We cannot
exclude that there is hypomethylation in other regions of the proviral
genome or in cellular genes that might activate HIV-1 production.
NFκB complex is themost frequent factor associatedwithHIV-1 rep-
lication (Coiras et al., 2009). No different NFκB activity was found be-
tween treated and untreated cells and then the increase of viral
production with 5-OHdC could not be associated with the activation
of the NFκB pathway as shown in a previous report (Witte et al., 2008).
None of the drugs or their combinations, speciﬁcally in the 5-OHdC
treated cells, affected signiﬁcantly the relative nucleotide concentra-
tions in the H61-D cells (Fig. 4). Thus, the possibility that imbalance of
nucleotide pools inﬂuenced viral replication in cells treated with 5-
OHdC is improbable. Although no signiﬁcant difference was obtained
with any of the factors studied, it cannot be excluded that a combination
of minor effects of these and other unidentiﬁed factors could be associ-
atedwith the increase in HIV-1 replication associated with the use of 5-
OHdC.
Toxic effect of the drugs, together with the need of its continuous
application to the culture and the long treatments allowing the
Table 1
Mutation frequency and type of mutations in HIV-1 LTR-gag region of intracellular viral RNA from of untreated and treated cultures after 54 passages.
Treatment Number of
clones
Mutation frequency a
(×10−4)
Mutation type; number (and percentage)
G–A G–T A–G A–T A–C T–A T–G T–C C–A C–G C–T Ins/Dels b
Control 29 5.7 1 (8.3) -c 7 (58) 1 (8.3) - - - 3 (25) - - - -/1
5-OHdC (C) 19 10.3 2 (14) - 4 (29) - - 1 (7) 1 (7) 5 (36) - 1 (7) - -
5-FU (F) 19 6.6 1 (11.1) - 3 (33.3) - - - - 5 (55) - - - -/2
Gemcitabine (G) 20 6.3 - - 6 (67) - - - - 3 (33) - - - -
C+G 19 9.5 3 (23) - 4 (31) - - - - 4 (31) 1 (8) - 1 (8) -
C+F 19 10.3 2 (14.3) - 4 (28.6) - 1 (7.1) - - 5 (35.7) - - 2 (14.3) -/1
F+G 20 9 - 1 (7.7) 5 (38.5) - - - - 3 (23.1) - - 4 (31) -/1
a Mutations per sequenced nucleotides.
b Insertion and deletions.
c Dash indicates absence of the corresponding mutation.
151C. Sánchez-Jiménez et al. / Virology 424 (2012) 147–153maintenance of at least a sustained 80% cell viability, permitted only
low drug concentrations. It is important to emphasize that drug toxicity
is dependent on the cell type as well as on the cellular uptake of the
mutagenic molecules and on the duration of the drug application. The
concentrations used in the studywere inferior for 5-FU and gemcitabine
to those used in other studies (Clouser et al., 2010; Sierra et al., 2000).
These low concentrations as compared with previous studies, could
explain the lack of mutagenic effect observed in the mutation
frequency (Table 1). However, these drugs exerted an antiviral effect
as shown by the decrease in viral production in the cultures (Fig. 2).
In contrast, the drug concentration reached in this study with 5-
OHdC was the same (1 mM) (Loeb et al., 1999) or half the drug con-
centrations (Tapia et al., 2005) used in the acute HIV-1 infections. In the
5-OHdC treated cells, viral mutation frequencywas superior than in the
5-FU and gemcitabine treated cultures or the control cells (Table 1), and
it was observed not only in the single treatment but also in the combi-
nations with 5-FU and gemcitabine, supporting the mutagenic activity
of the drug (Loeb et al., 1999; Tapia et al., 2005). It is unlikely that
unspeciﬁc toxic effects could contribute to the different effects of the
mutagens tested.
All the combination treatments showed a statistically signiﬁcant
effect on the mutation frequency in intracellular viral RNA that was
more signiﬁcant in the case of the combinations of 5-OHdC plus gem-
citabine and 5-FU and gemcitabine (Fig. 5). The lack of effect in the
single treatments with these drugs and the positive effect of itsFig. 5.Mean genetic heterogeneity of the intracellular HIV-1 RNA in H61-D cells treated
with mutagenic agents. The analysis was performed by sequence analysis of individual
molecular clones of HIV-1 from cells after 54 passages in the presence of the drugs or
drug combinations indicated in the abscissa (control correspond to 54 cell passages
in the absence of any drug). The mean heterogeneity is represented as the average
pair wise Hamming distance; standard error of the mean is indicated (SEM). Each
value was compared with the control population and the statistical signiﬁcance of
this comparison is indicated above the columns, where (**) implies a p-valueb0.01
and (***) a p-valueb0.0001. The corresponding mutation frequencies and mutation
types are given in Table 1. Procedures are described in Materials and methods.combination, are in agreement with a synergistic effect, as reported
for these mutagens (Clouser et al., 2010).
Treatment of HIV-1-infected individuals with highly active antire-
troviral therapy (HAART) has been highly successful in the control of
plasma viral load, and in the control of the AIDS epidemic in the de-
veloped nations. This success has been accompanied, however, by
the inevitable selection of antiretroviral-resistant viruses (Larder
and Kemp, 1989; Shafer et al., 2007). The eradication of the virus
from patients, however, has not been achieved with HAART due to
the long half-life of the HIV-1 reservoir cells, and consequently a
life-long antiretroviral treatment would be required for extinction
(Chun et al., 1997; Finzi et al., 1997; Siliciano et al., 2003). These lim-
itations promote the search of new antiretroviral strategies.
“In vivo” HIV-1 lethal mutagenesis is a new avenue for antiviral
treatment (Mullins et al., 2011). This strategy should take into account
not only the effect of the mutagens on the actively replicating T cells
in the patients but also in the persistently low-replicating cells as well
as in the latently infected cells. This study has investigated the effect
of mutagenic treatment on an HIV-1 persistently infected cell line,
with continuous viral replication, and it has demonstrated the difﬁculty
of viral eradication and the limited efﬁcacy of some mutagenic drugs.
Conclusions
This study has disclosed the unexpected effect of 5-OHdC on activa-
tion of HIV-1 replication in a persistently infected cell line. Although the
mechanism of 5-OHdC action is not yet elucidated, the enhancement
of viral replication by a mutagenic pyrimidine analog cautions
against the use, without prior investigation, of related molecules for
AIDS treatment.
Materials and methods
Cells
The chronically infected H61 cell line was established as detailed
in (Sanchez-Merino et al., 2007) by infection of lymphocytic H9
cells, with viral isolate s61 directly obtained from patient's PBMCs
(Sanchez-Palomino et al., 1993). Cells were maintained in RPMI
1640 medium (Bio-Whittaker) supplemented with 10% fetal bovine
serum, 4 mM glutamine and 100 uds/ml penicillin and 100 μg/ml
streptomycin at 37 °C in 5% CO2. Cellular viability was determined
by trypan-blue exclusion (Sigma).
H61 cell cloning
The H61-D cell line used in this study is a cell clone obtained from
H61 cells by limiting dilution. Cloning was performed in a 96 well pla-
que, after selecting the wells with only one cell under the microscope.
100 μl of medium mixed 1:1 with conditioned culture medium was
added and cultures were grown to obtain a cellular stock. Three
152 C. Sánchez-Jiménez et al. / Virology 424 (2012) 147–153cellular clones were obtained, and clone H61-D was selected because
it showed 100% positive cells for HIV-1 by immuno-ﬂuorescence, and
its culture supernatant showed the higher titer with a TCID50 of
4×104/ml.Cell immune-ﬂuorescence
Cells were incubated in immuno-ﬂuorescence glasses previously
treated with 50 μg/ml poly-L-lysine (Sigma) in phosphate buffered so-
lution (PBS) for 1 h at 37 °C and then ﬁxed for 10 min in 4% paraformal-
dehyde. Fixed cells were washed in PBS and permeabilized with 0.1%
Triton X-100 for 5 min. After blocking cells with 20% fetal bovine sera
(FBS), they were incubated for 30 min with HIV-1 positive serum dilut-
ed 1:50 and DAPI diluted 1:2000 in PBS, respectively (Invitrogen). After
washing 3 times in PBS, slides were incubated in the dark for 30 min
with 1:50 anti-human IgG antibody (Southern Biotechnology Associ-
ates, Inc) bound to FITC ﬂuorochrome. Preparations were mounted in
Mowioll 40–88 reagent (Sigma) and analyzed in a ﬂuorescent micro-
scope Leica DMRD supported with IM1000 software.Drugs
5-OHdC stands for 5-hydroxy-2′-deoxycytidine, 5-FU for 5-
ﬂuorouracil and gemcitabine for 2′,2′-diﬂuoro-2′-deoxycytidine. Stocks
were prepared by dissolving 5-OHdC (Berry & Associates) and 5-FU
(Sigma) in RPMI to a concentration of 82 mMand 10mg/ml, respective-
ly. Gemcitabine (Sigma) was dissolved in saline buffer solution (0.9%
NaCl) to a concentration of 152 mM. Stocks were stored at −20 °C
before use.Mutagenic treatments
H61-D cells were cultured in the presence of themutagenic drugs at
the appropriate concentrations during 54 passages. Cells were sub-
cultured three times a week at a concentration of 4×105 cells per milli-
liter of RPMI. Before the treatment passages, cells were washed 2 times
in PBS and resuspended in fresh culture medium containing the drugs.
Drug concentration was maintained constant during the passages by
addition of the drugs to the fresh medium. In gemcitabine cultures
drug was added only once a week.Determination of viral markers
Viral expressionwas assessed bymonitoring p24 protein concentra-
tion in cell culture supernatant using Elecsys HIV antigen detection
assay (Roche), and RT activity by using the Retro Sys RT Activity Kit
(Innovagen). Viral titer TCDI50 was determined in TZM-bl cells follow-
ing the protocol previously described in (Derdeyn et al., 2000).Bisulphyte HIV-1 LTR CpG methylation assay
DNA was obtained from 4×106 treated or untreated cells using the
QIAamp DNA Mini Kit (QIAGEN) and subjected to bisulphite modiﬁca-
tion using the CpGenome DNA Modiﬁcation Kit (Chemicon). Modiﬁed
DNA was ampliﬁed by PCR using primers designed to amplify a U3
LTR region rich in methylation sites. Primers were 5′-GAAGAGGTTAAT-
GAAGGAGAG-3′ (positions 171 to 191) and 5′-CCAAAAAACTCC-
CAAACTCA-3′ (complementary to positions 497 to 478). Primers are
numbered according to (Ratner et al., 1985). PCR conditions were
59 °C of annealing temperature, 2 mM MgCl2 and Taq polymerase.
PCR products were cloned using TOPO TA Cloning Kit (Invitrogen) and
sequenced in an ABI PRISM DNA analyzer.Nucleotide pool analysis
The procedure of (Pogolotti and Santi, 1982) was used with minor
modiﬁcations. H61-D cells (4×106) from passage 54 were washed
with PBS, treated with 600 μl of 0.6 M trichloroacetic acid and incu-
bated on ice for 10 min. The supernatants were extracted with
1,1,2-trichlorotriﬂuoroethane (Sigma) containing 0.5 M tri-n-
octylamine (Sigma), vortexed for 10 s and centrifuged 30 s at
12,000 g. The entire treatment was performed at 0–4 °C, using ice-
cold solutions. Samples consisting of 100 ml of cell extracts were
injected in a Waters Alliance 2695 series HPLC with a Partisil 10
SAX analytical column (4.6 mm×250 mm) and a Partisil 10 SAX
guard cartridge column (4.6×30 mm) (both from Capital HPLC), con-
nected to a Waters 2996 photodiode array detector. Nucleotides were
separated at an eluent ﬂow rate of 0.8 ml/min and detected at a
wavelength of 254 nm as follows. First, the column was equilibrated
with 30 ml of the low concentration buffer (7 mM NH4H2PO4, pH
3.8). After 18 min of an isocratic period with the low concentration
buffer a linear gradient to the high concentration buffer (250 mM
NH4H2PO4, 500 mM KCl, pH 4.5) was applied for 90 min. Finally, an
isocratic period of 22 min with the high concentration buffer was
used. Before starting a new run the column was regenerated with
60 ml of the low concentration buffer. A standard solution containing
1 nmol of each UTP, CTP, ATP and GTP, was chromatographed prior to
the analysis of cell extracts and the amount of each ribonucleotide in
the samples calculated by Waters EmpowerTM Chromatography Data
Software. NAD peak was determined by spectral analysis and used to
normalize nucleotide values. The effect of each treatment on the
levels of each nucleotide triphosphate was tested by a non-
parametric Kruskal–Wallis one-way analysis of variance.
Quasispecies analyses of intracellular HIV-1 RNA in the LTR-gag region
RNA was obtained from 4×106 cells using the RNeasy Mini Kit
(QIAGEN). Retrotranscription of RNA was done with oligo-dTTP18
(Sigma) and AMV Reverse Transcriptor (Promega). DNA ampliﬁcation
was realized using Expand High Fidelity (Roche) and PCR primers 5′-
GTCTCTCTGGTTAGACCAGATCTGAGCCTG-3′ (positions 456 to 485)
and 5′-GGTGATATGGCCTGATGTACCATTTGCCCCTG-3′ (complementary
to positions 1235 to1204). Primers are numbered according to the se-
quence of (Ratner et al., 1985). PCR conditions were 55 °C of annealing
temperature and 1.5 mM MgCl2. PCR amplicons were cloned using
TOPO TA Cloning Kit (Invitrogen) and sequenced in ABI PRISM DNA
analyzer.
Statistical analysis
Viral quasispecies heterogeneity in intracellular RNA from the trea-
ted and control cultures was calculated by pairwise Hamming distance
between each clone of the different treatments using MEGA 5.1 soft-
ware. Signiﬁcant difference of the mean genetic heterogeneity within
every virus of the treated cultures and the control population of
untreated passaged cells was tested using a Kruskal–Wallis test
followed by a Dunn's multiple comparison tests. The effect of treat-
ments on the level of each trinucleotide species was tested by the
non-parametric Kruskal–Wallis one-way analysis of variance.
Conﬂict of interest statement
The authors declare that they have no competing interests.
Acknowledgments
Technical support fromMaria Rosa López-Huertas, Maite Coiras, and
José Alcamí for the NFκB analysis and José Maria Rojas for the methyla-
tion experiments is greatly appreciated. Miguel Angel Martínez is
153C. Sánchez-Jiménez et al. / Virology 424 (2012) 147–153thanked for helpful suggestions and the critical reading of the manu-
script and Rafael FernándezMuñoz by statistical analysis in ribonucleo-
tide pools and two anonymous reviewers for the helpful comments.
Work in CNM is supported by grants SAF 2007–61036 and SAF
2010–17226, by Fundacion para la Investigacion y Prevencion del
SIDA en España (FIPSE) grants 36558/06, 36641/07, 36779/08,
360766/09 and in part by the Red Temática Cooperativa de Investiga-
ción en SIDA (Red de grupos 173) of the Fondo de Investigaciones
Sanitarias de la Seguridad Social (FISss). Support by grant BFU2007-
65080BMC from MICINN to AG-P is acknowledged. Work at CBMSO is
supported by grants BFU2008-02816/BMC, FIPSE 36558/06 and Funda-
ción Ramón Areces. CIBERehd is funded by Instituto de Salud Carlos III.
References
Agudo, R., Arias, A., Pariente, N., Perales, C., Escarmis, C., Jorge, A., Marina, A., Domingo,
E., 2008. Molecular characterization of a dual inhibitory and mutagenic activity of
5-ﬂuorouridine triphosphate on viral RNA synthesis. Implications for lethal muta-
genesis. J. Mol. Biol. 382 (3), 652–666.
Agudo, R., Ferrer-Orta, C., Arias, A., de la Higuera, I., Perales, C., Perez-Luque, R., Verdaguer,
N., Domingo, E., 2010. A multi-step process of viral adaptation to a mutagenic nucle-
oside analogue by modulation of transition types leads to extinction-escape. PLoS
Pathog. 6 (8), e1001072.
Anderson, J.P., Daifuku, R., Loeb, L.A., 2004. Viral error catastrophe by mutagenic nucle-
osides. Annu. Rev. Microbiol. 58, 183–205.
Beumer, J.H., Eiseman, J.L., Parise, R.A., Joseph, E., Holleran, J.L., Covey, J.M., Egorin, M.J.,
2006. Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyl-
transferase inhibitor 5-ﬂuoro-2′-deoxycytidine in mice. Clin. Cancer Res. 12 (24),
7483–7491.
Blazkova, J., Trejbalova, K., Gondois-Rey, F., Halfon, P., Philibert, P., Guiguen, A., Verdin,
E., Olive, D., Van Lint, C., Hejnar, J., Hirsch, I., 2009. CpG methylation controls reac-
tivation of HIV from latency. PLoS Pathog. 5 (8), e1000554.
Burris III, H.A., Moore, M.J., Andersen, J., Green, M.R., Rothenberg, M.L., Modiano, M.R.,
Cripps, M.C., Portenoy, R.K., Storniolo, A.M., Tarassoff, P., Nelson, R., Dorr, F.A., Ste-
phens, C.D., Von Hoff, D.D., 1997. Improvements in survival and clinical beneﬁt
with gemcitabine as ﬁrst-line therapy for patients with advanced pancreas cancer:
a randomized trial. J. Clin. Oncol. 15 (6), 2403–2413.
Chun, T.W., Carruth, L., Finzi, D., Shen, X., DiGiuseppe, J.A., Taylor, H., Hermankova, M.,
Chadwick, K., Margolick, J., Quinn, T.C., Kuo, Y.H., Brookmeyer, R., Zeiger, M.A.,
Barditch-Crovo, P., Siliciano, R.F., 1997. Quantiﬁcation of latent tissue reservoirs
and total body viral load in HIV-1 infection. Nature 387 (6629), 183–188.
Clouser, C.L., Patterson, S.E., Mansky, L.M., 2010. Exploiting drug repositioning for discov-
ery of a novel HIV combination therapy. J. Virol. 84 (18), 9301–9309.
Clouser, C.L., Holtz, C.M., Mullett, M., Crankshaw, D.L., Briggs, J.E., Chauhan, J., VanHoutan,
I.M., Patterson, S.E., Mansky, L.M., 2011. Analysis of the ex vivo and in vivo antiretro-
viral activity of gemcitabine. PLoS One 6 (1), e15840.
Coiras, M., Lopez-Huertas, M.R., Mateos, E., Alcami, J., 2008. Caspase-3-mediated cleavage
of p65/RelA results in a carboxy-terminal fragment that inhibits IkappaBalpha and en-
hances HIV-1 replication in human T lymphocytes. Retrovirology 5, 109.
Coiras, M., Lopez-Huertas, M.R., Perez-Olmeda, M., Alcami, J., 2009. Understanding HIV-1
latency provides clues for the eradication of long-term reservoirs. Nat. Rev. Microbiol.
7 (11), 798–812.
Contreras, A.M., Hiasa, Y., He, W., Terella, A., Schmidt, E.V., Chung, R.T., 2002. Viral RNA
mutations are region speciﬁc and increased by ribavirin in a full-length hepatitis C
virus replication system. J. Virol. 76 (17), 8505–8517.
Crotty, S., Cameron, C.E., Andino, R., 2001. RNA virus error catastrophe: direct molecular
test by using ribavirin. Proc. Natl. Acad. Sci. U. S. A. 98 (12), 6895–6900.
Dapp, M.J., Clouser, C.L., Patterson, S., Mansky, L.M., 2009. 5-Azacytidine can induce lethal
mutagenesis in human immunodeﬁciency virus type 1. J. Virol. 83 (22),
11950–11958.
Day, C.W., Smee, D.F., Julander, J.G., Yamshchikov, V.F., Sidwell, R.W., Morrey, J.D., 2005.
Error-prone replication of West Nile virus caused by ribavirin. Antiviral Res. 67 (1),
38–45.
Derdeyn, C.A., Decker, J.M., Sfakianos, J.N., Wu, X., O'Brien, W.A., Ratner, L., Kappes, J.C.,
Shaw, G.M., Hunter, E., 2000. Sensitivity of human immunodeﬁciency virus type 1
to the fusion inhibitor T-20 is modulated by coreceptor speciﬁcity deﬁned by the
V3 loop of gp120. J. Virol. 74 (18), 8358–8367.
Domingo, E., Escarmis, C., Lazaro, E., Manrubia, S.C., 2005. Quasispecies dynamics and
RNA virus extinction. Virus Res. 107 (2), 129–139.
Eigen, M., 2002. Error catastrophe and antiviral strategy. Proc. Natl. Acad. Sci. U. S. A. 99
(21), 13374–13376.
Finzi, D., Hermankova, M., Pierson, T., Carruth, L.M., Buck, C., Chaisson, R.E., Quinn, T.C.,
Chadwick, K., Margolick, J., Brookmeyer, R., Gallant, J., Markowitz, M., Ho, D.D.,
Richman, D.D., Siliciano, R.F., 1997. Identiﬁcation of a reservoir for HIV-1 in
patients on highly active antiretroviral therapy. Science 278 (5341), 1295–1300.Graci, J.D., Cameron, C.E., 2008. Therapeutically targeting RNA viruses via lethal muta-
genesis. Future Virol. 3 (6), 553–566.
Grande-Perez, A., Sierra, S., Castro,M.G., Domingo, E., Lowenstein, P.R., 2002.Molecular in-
determination in the transition to error catastrophe: systematic elimination of lym-
phocytic choriomeningitis virus through mutagenesis does not correlate linearly
with large increases in mutant spectrum complexity. Proc. Natl. Acad. Sci. U. S. A. 99
(20), 12938–12943.
Grande-Perez, A., Gomez-Mariano, G., Lowenstein, P.R., Domingo, E., 2005a. Mutagenesis-
induced, large ﬁtness variations with an invariant arenavirus consensus genomic
nucleotide sequence. J. Virol. 79 (16), 10451–10459.
Grande-Perez, A., Lazaro, E., Lowenstein, P., Domingo, E., Manrubia, S.C., 2005b. Sup-
pression of viral infectivity through lethal defection. Proc. Natl. Acad. Sci. U. S. A.
102 (12), 4448–4452.
Harris, K.S., Brabant, W., Styrchak, S., Gall, A., Daifuku, R., 2005. KP-1212/1461, a nucleo-
side designed for the treatment of HIV by viral mutagenesis. Antiviral Res. 67 (1), 1–9.
Holland, J.J., Domingo, E., de la Torre, J.C., Steinhauer, D.A., 1990. Mutation frequencies
at deﬁned single codon sites in vesicular stomatitis virus and poliovirus can be in-
creased only slightly by chemical mutagenesis. J. Virol. 64 (8), 3960–3962.
Ishida, T., Hamano, A., Koiwa, T., Watanabe, T., 2006. 5′ long terminal repeat (LTR)-
selective methylation of latently infected HIV-1 provirus that is demethylated
by reactivation signals. Retrovirology 3, 69.
Larder, B.A., Kemp, S.D., 1989. Multiple mutations in HIV-1 reverse transcriptase confer
high-level resistance to zidovudine (AZT). Science 246 (4934), 1155–1158.
Leone, G., Voso, M.T., Teoﬁli, L., Lubbert, M., 2003. Inhibitors of DNA methylation in the
treatment of hematological malignancies and MDS. Clin. Immunol. 109 (1), 89–102.
Loeb, L.A., Essigmann, J.M., Kazazi, F., Zhang, J., Rose, K.D., Mullins, J.I., 1999. Lethal mu-
tagenesis of HIV with mutagenic nucleoside analogs. Proc. Natl. Acad. Sci. U. S. A. 96
(4), 1492–1497.
Mullins, J.I., Heath, L., Hughes, J.P., Kicha, J., Styrchak, S., Wong, K.G., Rao, U., Hansen, A.,
Harris, K.S., Laurent, J.P., Li, D., Simpson, J.H., Essigmann, J.M., Loeb, L.A., Parkins, J.,
2011. Mutation of HIV-1 genomes in a clinical population treated with the muta-
genic nucleoside KP1461. PLoS One 6 (1), e15135.
Perales, C., Agudo, R., Domingo, E., 2009. Counteracting quasispecies adaptability: ex-
tinction of a ribavirin-resistant virus mutant by an alternative mutagenic treat-
ment. PLoS One 4 (5), e5554.
Pogolotti Jr., A.L., Santi, D.V., 1982. High-pressure liquid chromatography–ultraviolet
analysis of intracellular nucleotides. Anal. Biochem. 126 (2), 335–345.
Ratner, L., Haseltine, W., Patarca, R., Livak, K.J., Starcich, B., Josephs, S.F., Doran, E.R.,
Rafalski, J.A., Whitehorn, E.A., Baumeister, K., et al., 1985. Complete nucleotide se-
quence of the AIDS virus, HTLV-III. Nature 313 (6000), 277–284.
Ruiz-Jarabo, C.M., Ly, C., Domingo, E., de la Torre, J.C., 2003. Lethal mutagenesis of the
prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology 308
(1), 37–47.
Sanchez-Merino, V., Munoz, L., Perez-Pastrana, M.E., Herrera, M.I., Olivares, I., Lopez-
Galindez, C., 2007. Genetic changes associated with distinct patterns of HIV type
1 persistence in chronically infected cell lines. AIDS Res. Hum. Retroviruses 23
(2), 251–260.
Sanchez-Palomino, S., Rojas, J.M., Martinez, M.A., Fenyo, E.M., Najera, R., Domingo, E.,
Lopez-Galindez, C., 1993. Dilute passage promotes expression of genetic and phe-
notypic variants of human immunodeﬁciency virus type 1 in cell culture. J. Virol.
67 (5), 2938–2943.
Severson, W.E., Schmaljohn, C.S., Javadian, A., Jonsson, C.B., 2003. Ribavirin causes error
catastrophe during Hantaan virus replication. J. Virol. 77 (1), 481–488.
Shafer, R.W., Rhee, S.Y., Pillay, D., Miller, V., Sandstrom, P., Schapiro, J.M., Kuritzkes,
D.R., Bennett, D., 2007. HIV-1 protease and reverse transcriptase mutations for
drug resistance surveillance. AIDS 21 (2), 215–223.
Sierra, S., Davila, M., Lowenstein, P.R., Domingo, E., 2000. Response of foot-and-mouth
disease virus to increased mutagenesis: inﬂuence of viral load and ﬁtness in loss of
infectivity. J. Virol. 74 (18), 8316–8323.
Sierra, M., Airaksinen, A., Gonzalez-Lopez, C., Agudo, R., Arias, A., Domingo, E., 2007.
Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: im-
plications for error catastrophe. J. Virol. 81 (4), 2012–2024.
Siliciano, J.D., Kajdas, J., Finzi, D., Quinn, T.C., Chadwick, K., Margolick, J.B., Kovacs, C.,
Gange, S.J., Siliciano, R.F., 2003. Long-term follow-up studies conﬁrm the stability
of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9 (6), 727–728.
Streeter, D.G., Witkowski, J.T., Khare, G.P., Sidwell, R.W., Bauer, R.J., Robins, R.K., Simon,
L.N., 1973. Mechanism of action of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxa-
mide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. U. S.
A. 70 (4), 1174–1178.
Tapia, N., Fernandez, G., Parera, M., Gomez-Mariano, G., Clotet, B., Quinones-Mateu, M.,
Domingo, E., Martinez, M.A., 2005. Combination of a mutagenic agent with a re-
verse transcriptase inhibitor results in systematic inhibition of HIV-1 infection. Vi-
rology 338 (1), 1–8.
Witte, V., Laffert, B., Gintschel, P., Krautkramer, E., Blume, K., Fackler, O.T., Baur, A.S.,
2008. Induction of HIV transcription by Nef involves Lck activation and protein ki-
nase C theta raft recruitment leading to activation of ERK1/2 but not NF kappa B.
J. Immunol. 181 (12), 8425–8432.
Zimmerman, T.P., Wolberg, G., Duncan, G.S., 1978. Inhibition of lymphocyte-mediated
cytolysis by 3-deazaadenosine: evidence for a methylation reaction essential to
cytolysis. Proc. Natl. Acad. Sci. U. S. A. 75 (12), 6220–6224.
